Advancing Alternative Bioequivalence for OINDPs
Nanopharm & Fluidda explore FDA’s progress in alternative bioequivalence for OINDPs, Model Master Files (MMF), and future regulatory pathways.
In Silico Bioequivalence Beyond Generic Drug Development
Nanopharm & Fluidda discuss FDA’s in silico bioequivalence methods for alternative pathways beyond generics in inhalation drug development.
FDA’s Evolving Stance on In-Silico Studies in Bioequivalence Testing
Discover how the FDA’s evolving view on in-silico methods, with insights from Nanopharm and FLUIDDA, impacts bioequivalence and generic drugs.
FDA New Inhaled Product Guidelines: Bioequivalence & PSGs
Explore Nanopharm & Fluidda discuss FDA’s revised inhaled product guidelines (PSGs) and alternative bioequivalence pathways for generics.
Nanopharm & Fluidda Discuss FDA’s New Inhaled Product Guidelines
Explore how alternative bioequivalence methods, including computational fluid dynamics and in silico modeling, are shaping the future of generic drug approval.
Novel Aerosol Apparatus for Inhaler Testing in OINDPs
Explore a case study for UniDose in the development of a novel aerosol collection apparatus for dissolution testing of orally inhaled drugs.
Nanopharm Value Creation with OINDP Innovation
Discover Nanopharm’s pre-clinical OINDP solutions using SmartTrack for cutting-edge MDI development, transforming respiratory drug research.
Nanopharm Case Study on Computational Modelling
Accelerate injectable drug reformulation for nasal delivery using modelling. Uncover clinical benefits and innovation in nasal pharmaceuticals.
Dual Excipient Integration in Dry Powder Inhaler Products
Nanopharm explore the effect of dual excipients on DPI products, boosting performance and shaping formulation in the dry powder inhaler landscape.
Nanopharm Newsletter May 2023
Explore Nanopharm’s SmartTrack™ for OINDPs and uncover the role of PBPK in nasal drug delivery.
